11 studies found for:    "Carcinoma, Pancreatic Ductal"
Show Display Options
Rank Status Study
1 Unknown  Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
Condition: Carcinoma, Pancreatic Ductal
Interventions: Drug: Paclitaxel and gemcitabine;   Procedure: Hyperfractionated external beam irradiation
2 Active, not recruiting A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002
Conditions: Carcinoma, Pancreatic Ductal;   Pancreatic Cancer;   Pancreatic Disease
Interventions: Biological: AGS-1C4D4;   Biological: gemcitabine
3 Unknown  Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer
Condition: Carcinoma, Pancreatic Ductal
Interventions: Drug: Targeted Therapy Tailored Treatment;   Drug: Standard Chemotherapy
4 Recruiting Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
Condition: Carcinoma, Pancreatic Ductal
Interventions: Drug: Atu027 & gemcitabine in lead in safety period;   Drug: Atu027 & gemcitabine in treatment arm 1;   Drug: Atu027 & gemcitabine in treatment arm 2
5 Completed
Has Results
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
Condition: Carcinoma, Pancreatic Ductal
Interventions: Drug: AG-013736;   Drug: Gemcitabine;   Drug: placebo
6 Terminated Amatuximab for High Mesothelin Cancers
Conditions: Carcinoma, Pancreatic Ductal;   Mesothelioma;   Ovarian Neoplasms;   Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Amatuximab (MORab-009)
7 Completed A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Conditions: Carcinoma, Pancreatic Ductal;   Pancreatic Cancer;   Pancreatic Disease
Interventions: Biological: AGS-1C4D4;   Biological: Gemcitabine
8 Completed Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: INNO-206
9 Recruiting Phase 2A Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Conditions: Metastatic Pancreatic Cancer;   Metastatic Colorectal Cancer
Intervention: Drug: NPC-1C/NEO-102
10 Recruiting PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: PEGPH20+nab-paclitaxel+gemcitabine;   Drug: nab-paclitaxel + gemcitabine
11 Completed CT Pancreas Perfusion
Conditions: Pancreatic Ductal Adenocarcinoma;   Chronic Pancreatitis;   Autoimmune Pancreatitis
Intervention:

Indicates status has not been verified in more than two years